Zhai Changyun, Gu Ke, Zhai Xiaoming, Wang Jianping, Zhang Junning
Clin Lab. 2017 Nov 1;63(11):1777-1785. doi: 10.7754/Clin.Lab.2017.170323.
Serum-lactate dehydrogenase (S-LDH) is reported to be associated with poor survival in patients with nasopharyngeal carcinoma (NPC); however, the results are inconsistent. The aim of the study was to perform a meta-analysis to evaluate the prognostic value of S-LDH in patients with NPC.
PubMed and Web of Science were searched for relevant studies, and the fixed-effects model was employed to pool the hazard risks (HRs) from individual studies when no substantial heterogeneity was detected; otherwise, the random-effects model was used. Heterogeneity and publication bias were also analyzed.
A total of 18 studies involving 13,789 patients were included in the meta-analysis, serum LDH level was associated with worse outcome in NPC patients. The combined HR for overall survival (OS) was 1.86 (95% confidence interval [CI]: 1.66 - 2.08; p < 0.01), and the pooled HRs for disease-free survival (DFS), distant metastasisfree survival (DMFS), and distant local relapse-free survival (LRFS) were 1.64 (95% CI: 1.45 - 1.86), 2.64 (95% CI: 2.15 - 3.25), and 2.59 (95% CI: 1.74 - 3.87), respectively.
Our results suggest that higher serum LDH level is associated with worse survival in patients with NPC, which is helpful for a personalized treatment strategy for NPC patients.
血清乳酸脱氢酶（S-LDH）据报道与鼻咽癌（NPC）患者的不良生存相关；然而，结果并不一致。本研究的目的是进行一项荟萃分析，以评估S-LDH在NPC患者中的预后价值。
检索PubMed和Web of Science以获取相关研究，当未检测到实质性异质性时，采用固定效应模型汇总个体研究的风险比（HRs）；否则，使用随机效应模型。还分析了异质性和发表偏倚。
荟萃分析共纳入18项研究，涉及13789例患者，血清LDH水平与NPC患者较差的预后相关。总生存（OS）的合并HR为1.86（95%置信区间[CI]：1.66 - 2.08；p < 0.01），无病生存（DFS）、无远处转移生存（DMFS）和无远处局部复发生存（LRFS）的汇总HR分别为1.64（95%CI：1.45 - 1.86）、2.64（95%CI：2.15 - 3.25）和2.59（95%CI：1.74 - 3.87）。
我们的结果表明，较高的血清LDH水平与NPC患者较差的生存相关，这有助于为NPC患者制定个性化治疗策略。
